biotech · Parkinson Disease · Amyotrophic Lateral Sclerosis · DNLI
Denali Therapeutics
Denali Therapeutics is a biotech organization headquartered in South San Francisco, USA. It trades on NYSE under ticker DNLI. Primary therapeutic focus areas include Parkinson Disease, Amyotrophic Lateral Sclerosis, Fron
Company details
- Status
- Public
- HQ
- 161 Oyster Point Blvd, South San Francisco, California 94080, US
- Founded
- 2015
- Employees
- 567
- Programs
- 23
- Drugs
- 10
- Patents
- 42
Quick answer
Denali Therapeutics is a biotech organization headquartered in South San Francisco, USA. It trades on NYSE under ticker DNLI. Primary therapeutic focus areas include Parkinson Disease, Amyotrophic Lateral Sclerosis, Frontotemporal Dementia (FTD), Mucopolysaccharidosis Type II [MPS II], Hunter Syndrome (Mucopolysaccharidosis Type II [MPS II]). NovaPharmaNews links 23 clinical program(s), 1 drug profile(s), and 42 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 1 (13), phase 2 (6), phase 3 (4).
Company snapshot
Denali Therapeutics is a biotechnology company pioneering a new class of biotherapeutics designed to cross the blood-brain barrier using our proprietary TransportVehicle™ platform. We discover, develop and deliver medicines for people living with neurodegenerative, lysosomal storage and other serious diseases.
- 1 approved product(s) across US/EU regulatory metadata.
- 23 active pipeline program(s) linked via ClinicalTrials.gov.
- 42 US patent(s) indexed to this assignee profile.
Public regulatory, clinical, patent, and corporate records for Denali Therapeutics. Not investment advice.
Recent coverage
Biogen and Denali's Parkinson's Drug Trial: What Went Wrong?
Biogen and Denali's recent trial for a Parkinson's drug has not met expectations, raising questions about future strategies and investments in this space.
Biogen and Denali Abandon Parkinson's Drug After Study Setback
Biogen and Denali have decided to discontinue their drug for non-genetic Parkinson's disease following disappointing mid-stage study results. This article explores the implications for the pharmaceutical landscape.
Top assets
Lead pipeline drugs
- Marketed / approved
- Marketed / approved
- approved
- approved
Active clinical programs
- Phase 3
- Phase 3
- Phase 3
- Phase 3
Momentum
Proprietary activity score for Denali Therapeutics.
2 active signals
Signal breakdown
- Clinical trials
- Nova articles
- Patents filed
- FDA actions
- SEC filings
- Conference presentations
- Pipeline advances
Competitor landscape
Therapeutic-area overlap peers from registry and pipeline signals.
- Peer + 0 momentum
- Peer + 0 momentum
Recent activity
Latest pipeline, patent, and corporate events for Denali Therapeutics.
- Clinical update
- Clinical update
- Clinical update
- Clinical update
Elaprase 2 mg/ml concentrate for solution for infusion — Phase 3
- Clinical update
Quick answers
Common questions about this sponsor — for analysts and search.
-
What is Denali Therapeutics?
-
Is Denali Therapeutics publicly traded?
-
What drugs does Denali Therapeutics develop or market?
-
What are the latest developments for Denali Therapeutics?
-
What therapeutic areas does Denali Therapeutics focus on?
Therapeutic focus
Therapeutic area distribution
Pipeline concentration by therapeutic area from linked clinical programs.